Abiopharma

🔍 Basso Stephen (Executive)

Company: Innoviva, Inc. (INVA)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 37,994 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: false | shares_owned_after: 88,007.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 93,750 shares of Non-statutory Stock Option at $22.99 per share (Derivative)
  Date: 2026-05-04 | Code: A | Expires: 2036-05-03 | Exercise: 2027-02-20 | equity_swap_involved: false | shares_owned_after: 93,750.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The Reporting Person was conditionally granted time-vested restricted stock units ("RSUs") and non-statutory stock options ("Options"). The RSUs and Options were granted subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan at the Issuer's 2026 annual meeting of stockholders on May 4, 2026, as disclosed in the Issuer's Schedule 14A filed with the Securities and Exchange Commission ("SEC") on March 24, 2026.
• F2: Twenty-five percent of each of the RSUs and Options vest on February 20, 2027 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) with respect to the Options, in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan) in which the options are not assumed or replaced, provided that the Reporting Person has not experienced a termination prior to such "change in control," or (ii) with respect to the Options and the RSUs, in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control" where such awards are assumed or substituted, subject to an effective release of claims.